Wound assessment: Daily wound inspection obese patients develop deeper infections that may not be visible on surface initially
Study finds semaglutide reduces CKD progression and CV death risk in patients with diabetes and CKD By Rebecca Jenkins Once weekly treatment with semaglutide reduces the risk of major kidney disease events and death from cardiovascular (CV) causes in patients with type 2 diabetes and chronic kidney disease (CKD), an Australian-led international trial has found
Saxendas active ingredient, liraglutide, has a half-life (a way of measuring how long the drug sticks around in your system) of about 13 hours
But the margin for error tightens
But, so, when someone is not simply looking to lose weight, but maybe hyperglycemic and has peripheral insulin resistance, and maybe some of the cardiovascular sequelae, and you do your pooled cohort risk equation like you did for James, and its meaningfully over 7.5, We finally have some strategies that we can implement to make life-saving treatments more efficacious